WHO Issues New Clinical Advice On Treating Covid-19 Patients

Geneva : The World Health Organization (WHO) issued fresh clinical advice on Tuesday for treating COVID-19 patients, including those displaying persistent symptoms after recovery, and also said it advised using low-dose anti-coagulants to prevent blood clots.

“The other things in the guidance that are new are that COVID-19 patients at home should have the use of pulse oximetry, that’s measuring the oxygen levels, so you can identify whether somewhat at home is deteriorating and would be better off having hospital care,” WHO spokeswoman Margaret Harris told a U.N. briefing in Geneva.

The WHO advised clinicians to put patients into the awake prone position, on their front, shown to improve the oxygen flow, she said.

“Also we recommend, we suggest the use, of low-dose anti-coagulents to prevent blood clots forming in blood vessels. We suggest the use of lower doses rather than higher doses because higher doses may lead to other problems,” Harris said.

She added that a WHO-led team of independent experts, currently in the central Chinese city of Wuhan where the first human cases were detected in December 2019, is due to leave quarantine in the next two days to pursue its work with Chinese researchers on the virus origins.

She declined to commment on reports of delays in roll-out of vaccines in the European Union. She said she had no specific data and the WHO’s priority was for health workers in all countries to be vaccinated in the first 100 days of the year.

AstraZeneca, which developed its shot with Oxford University, told the EU on Friday it could not meet agreed supply targets up to the end of March.

Related Posts

Ajanta Pharma Promoter Sell 3% Stake Worth ₹1,024 Crore; Shares Trade Higher

Mumbai: A promoter entity of Ajanta Pharma Ltd. on Tuesday offloaded a nearly 3% stake in the company through open market transactions, even as domestic institutional investors stepped in to absorb a large…

FDA cracks down on illegal drug trade, stock worth about ₹25 lakh seized from Pune and Kolhapur

Pune: In a major crackdown against illegal pharmaceutical activities that compromise public health, the Food and Drug Administration (FDA) has seized a stock of medicines worth above Rs24.81 lakh from…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Ajanta Pharma Promoter Sell 3% Stake Worth ₹1,024 Crore; Shares Trade Higher

Ajanta Pharma Promoter Sell 3% Stake Worth ₹1,024 Crore; Shares Trade Higher

FDA cracks down on illegal drug trade, stock worth about ₹25 lakh seized from Pune and Kolhapur

FDA cracks down on illegal drug trade, stock worth about ₹25 lakh seized from Pune and Kolhapur

ICMR-NIN study links micronutrient deficiencies to higher dementia risk

ICMR-NIN study links micronutrient deficiencies to higher dementia risk

Pvt nursing home sealed in Chatra after woman, unborn baby die

Pvt nursing home sealed in Chatra after woman, unborn baby die

30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

Scheme to build bulk drugs’ R&D, capacity in works, says Pharma secy

Scheme to build bulk drugs’ R&D, capacity in works, says Pharma secy